Literature DB >> 16952920

Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam study.

Laura C van Vark1, Isabella Kardys, Gysèle S Bleumink, Anneke M Knetsch, Jaap W Deckers, Albert Hofman, Bruno H Ch Stricker, Jacqueline C M Witteman.   

Abstract

AIMS: Evidence is accumulating that inflammation plays a role in the pathophysiology of heart failure. Lipoprotein-associated phospholipase A2 (Lp-PLA2) has pro-inflammatory properties. We investigated whether Lp-PLA2 activity is associated with heart failure. METHODS AND
RESULTS: Lp-PLA2 activity was determined in a random sample of 1820 subjects from the Rotterdam Study, a population-based cohort study among persons aged 55 years and over. During a mean follow-up of 6.7 years, 94 heart failure cases occurred. We excluded participants with heart failure or coronary heart disease at baseline and we accounted for incident coronary heart disease during follow-up. We used Cox proportional hazard models to compute hazard ratios adjusted for age, sex, non-HDL cholesterol, HDL cholesterol, body mass index, systolic blood pressure, diastolic blood pressure, hypertension, diabetes mellitus, smoking, and C-reactive protein. The hazard ratio per unit increase of Lp-PLA2 activity was 1.03 [95% confidence interval (95% CI 1.01-1.05]; P for trend was 0.011. Hazard ratios for the second, third, and fourth quartiles were 1.06 (95% CI 0.55-2.04), 1.43 (95% CI 0.73-2.81), and 2.33 (95% CI 1.21-4.49), respectively, using the lowest quartile of Lp-PLA2 activity as the reference category.
CONCLUSION: This study suggests that Lp-PLA2 activity is independently associated with incident heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16952920     DOI: 10.1093/eurheartj/ehl230

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Determination of phospholipase activity of PAF acetylhydrolase.

Authors:  Diana M Stafforini; Thomas M McIntyre
Journal:  Free Radic Biol Med       Date:  2012-05-29       Impact factor: 7.376

2.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

3.  The Rotterdam Study: 2014 objectives and design update.

Authors:  Albert Hofman; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2013-11-21       Impact factor: 8.082

4.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

Review 5.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

6.  Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.

Authors:  Yariv Gerber; Shannon M Dunlay; Allan S Jaffe; Joseph P McConnell; Susan A Weston; Jill M Killian; Véronique L Roger
Journal:  Atherosclerosis       Date:  2008-08-07       Impact factor: 5.162

7.  Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure.

Authors:  W H Wilson Tang; Ronit Katz; Marie-Luise Brennan; Ronnier J Aviles; Russell P Tracy; Bruce M Psaty; Stanley L Hazen
Journal:  Am J Cardiol       Date:  2009-03-13       Impact factor: 2.778

8.  Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.

Authors:  Takeki Suzuki; Cam Solomon; Nancy Swords Jenny; Russell Tracy; Jeanenne J Nelson; Bruce M Psaty; Curt Furberg; Mary Cushman
Journal:  Circ Heart Fail       Date:  2009-06-19       Impact factor: 8.790

9.  Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Demosthenis B Panagiotakos; Christos Pitsavos; Christodoulos Stefanadis; Smaragdi Antonopoulou
Journal:  Lipids Health Dis       Date:  2009-06-05       Impact factor: 3.876

10.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.